UK Community Advisory Board (UK-CAB)

CAB44: Generics and drug development

Friday 19 October 2012

Draft programme:

09:30 – 09:50 Registration, refreshments and expenses
09:50 -10:00 Welcome, introductions, UKCAB updates
10:00 -11:00 Drug development process  and introduction  to generics – Rebecca McDowall, HIV i-Base
Drug development in relation to PrEP and the PROUD studies – David Dolling, MRC
11:00 – 11.15 Break
11:15 – 12.30 Generic HIV drugs – Katy Athersuch, Medical Innovation & Access Policy Adviser, MSF
12:30 – 14:00 Lunch
14:00 – 15:30 Conferences feedback by UKCAB members:
Silvia Petretti/Angelina Namiba – Women/advocacy and Option B+
Robert James – AIDS2012 – History and Hepatitis
Roger Pebody – IAS, BHIVA
Chris O’Connor – Washington Snapshot
Damian  Kelly – WAC Feedback; Living2012, 2015 Pledge
15.30 – 15.35 Break
15:35 – 16:00 UKCAB AOB
16.00 Close

Background reading:

Generic HIV drugs will widen US treatment net

The Doha declaration explained

Robin Hood tax (announced by Francois Hollande at IAS)

AIDS, drug prices and generic drugs

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.